title: Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
abstract: OBJECTIVE
  To describe HIV RNA levels during tuberculosis (TB) infection in patients co-infected with TB and HIV. Moreover, to examine the p24 antigen profile during TB treatment.
  
  
  METHODS
  We examined the changes in CD4 cell count, HIV RNA, and p24 levels during anti-tuberculous therapy in a group of TB/HIV-1 co-infected and HIV-untreated patients from Guinea-Bissau.
  
  
  RESULTS
  A total of 365 TB patients were enrolled, of whom 76 were co-infected with HIV-1 and 19 were dually infected with HIV-1 + HIV-2. No significant changes in CD4, HIV RNA, or p24 levels were found during 8 months of TB treatment. HIV RNA levels correlated well with p24 (Spearman's R(2)=0.52, p<0.00001) and both markers were strong predictors of mortality. Initial HIV RNA levels correlated with a clinical TB severity index--the TBscore (Spearman's R(2)=0.23, p=0.02)--and the TBscore decreased dramatically during TB treatment although HIV RNA levels remained unchanged.
  
  
  CONCLUSIONS
  We found no significant changes in CD4, HIV RNA, or p24 antigen levels during 8 months of TB treatment among TB/HIV co-infected individuals, who did not receive antiretroviral treatment. The markers were unaffected by a strong improvement in TBscore and all three markers showed predictive capacity for mortality risk.
authors.affiliation: Department of Infectious Diseases, Aarhus University Hospital, Brendstrupgaardsvej, 8200 Aarhus N, Denmark; GloHAU, Center for Global Health, School of Public Health, Aarhus University, Aarhus, Denmark. Electronic address: wejse@dadlnet.dk.
authors.forename: C
authors.initials: C
authors.lastname: Wejse
authors.forename: A
authors.initials: A
authors.lastname: Furtado
authors.forename: C
authors.initials: C
authors.lastname: Camara
authors.forename: M
authors.initials: M
authors.lastname: Lüneborg-Nielsen
authors.forename: M
authors.initials: M
authors.lastname: Sodemann
authors.forename: J
authors.initials: J
authors.lastname: Gerstoft
authors.forename: T L
authors.initials: TL
authors.lastname: Katzenstein
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D060085:Coinfection / Q000097:blood / Q000276:immunology* / Q000401:mortality; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006169:Guinea-Bissau; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000276:immunology* / Q000401:mortality; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000494:pharmacology / Q000627:therapeutic use; D012367:RNA, Viral; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D014807:Vitamin D / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D015415:Biomarkers; D016655:HIV Core Protein p24; D012367:RNA, Viral; D014807:Vitamin D; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
keywords: CD4 count; Clinical score; HIV RNA; Tuberculosis; p24 antigen